T. Rowe Price Associates
DMRA

T. Rowe Price Associates’s Damora Therapeutics DMRA Stock Holding History

T. Rowe Price Associates’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
+48,743
New +$1.18M ﹤0.01% 2213

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

T. Rowe Price Associates's DMRA Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 48,743 shares worth $1.27M. The stake represents ﹤0.01% of the portfolio and ranks #2213 among its holdings.

104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • T. Rowe Price Associates held 48,743 shares of Damora Therapeutics worth $1.27M as of Q2 2026.
  • Damora Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2213 holding.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.